While this analysis is hypothesis generating, the results demonstrate the potential of measuring ctDNA throughout treatment to detect tumor progression, as well as of identifying genetic alterations that have clinical implications in HR + /HER2 − ABC. The gene discussed is ERBB2; the disease is neoplasm.